Serbia - serbisk - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

pharmaswiss d.o.o., beograd - мегестрола - tableta - 160mg

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - megestrol acetate -

Irland - engelsk - HPRA (Health Products Regulatory Authority)

bristol-myers squibb (holdings) limited - megestrol acetate - oral suspension - 40

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pharmaswiss ceska republika s.r.o. - megestrol acetate - tablet - 160 milligram(s) - progestogens; megestrol

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

bausch & lomb uk ltd - megestrol acetate - oral tablet - 160mg

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - megestrol acetate 160mg;   - tablet - 160 mg - active: megestrol acetate 160mg   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

bausch health ireland limited, dublin array - 885 megestrol-acetÁt - tableta - 160mg - megestrol

USA - engelsk - NLM (National Library of Medicine)

stat rx usa - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - megace ® es (megestrol acetate) oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). history of hypersensitivity to megestrol acetate or any component of the formulation. known or suspected pregnancy.

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - megace® es oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). enter section text here therapy with megestrol acetate for weight loss should only be instituted after treatable causes of weight loss are sought and addressed. these treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. megestrol acetate is not intended for prophylactic use to avoid weight loss. enter section text here history of hypersensitivity to megestrol acetate or any component of the formulation. known or suspected pregnancy. enter section text here pregnancy category x [ see warnings and precautions: (5.2)]. no adequate animal teratology information is available at clinically relevant doses. pregnant rats treated with low doses of megestrol acetate (0.02-fold the recommen

USA - engelsk - NLM (National Library of Medicine)

endo pharmaceuticals inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - megace es is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). limitations of use therapy with megace es for weight loss should only be insti­tuted after treatable causes of weight loss are sought and addressed. these treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. megace es is not intended for prophylactic use to avoid weight loss. - history of hypersensitivity to megestrol acetate or any component of the formulation. - pregnancy [see warnings and precautions (5.2), use in specific populations (8.1, 8.3)]. risk summary based on animal data, megestrol acetate may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy [see contraindications (4)] . there are no available human data to assess for any drug-associated risks of miscar